NICE put on defensive as ruling on Relenza ends in row over 'leaks'

By Tash Shifrin1999-10-07T00:00:00

The National Institute for Clinical Excellence has defended its handling of the fast-track appraisal of Relenza, despite concern about the way news that the anti-flu drug had been turned down for NHS prescription this winter emerged.

You need to be signed in to read more

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

All of HSJ.co.uk and our HSJ mobile app
News and insight on all areas of public funded healthcare
Expert commentary, insight and analysis from industry leaders
9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

to HSJ

Sign into your account here